News RepliCel Life Sciences Inc. Toronto S.E.

Equities

RP

CA76027P4006

Market Closed - Toronto S.E. Other stock markets 11:00:00 2024-04-16 am EDT			5-day change	1st Jan Change
0.055 ^CAD	0.00%		0.00%	-15.38%

2023	RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RepliCel Life Sciences : Announces Secured Loan Agreement	Apr. 18	PU
RepliCel Life Sciences : announces a Letter of Intent for Asset Purchase Agreement - Form 6-K	Mar. 20	PU
RepliCel Life Sciences : Letter of Intention (Asset Purchase)	Mar. 18	PU
Canadian Investment Regulatory Organization Trading Halt - RP	Mar. 15	AQ
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	Nov. 30	PU
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
RepliCel Life Sciences : Arbitration decision	Nov. 16	PU
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	23-10-24	PU
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-10-23	CI
RepliCel Life Sciences : AGM 2023 Zoom Link and Materials	23-09-21	PU
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	23-08-30	CI
RepliCel Life Sciences : Notice of Meeting and Record Date - Form 6-K	23-08-17	PU
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	23-08-17	CI
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	23-08-17	CI
REPLICEL LIFE SCIENCES : STATEMENT OF EXECUTIVE COMPENSATION - Form 6-K	23-08-10	PU
RepliCel Life Sciences : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	23-05-31	PU
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
RepliCel Life Sciences : Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options - Form 6-K	23-05-18	PU
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-01	CI
RepliCel Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	23-04-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News RepliCel Life Sciences Inc. Toronto S.E.

Equities

RP

CA76027P4006

Summary

Filters